Cat. No.: HY-B1029

Danazol

4 Cited Publications

고객리뷰

Based on 4 publication(s) in Google Scholar

Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.66%
CAS No.: 17230-88-5
화학식: C₂₂H₂₇NO₂
분자량:337.46

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Danazol Chemical Structure

CAS No.: 17230-88-5

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- Clinical Trial
Chemical Information
Publications (4)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All PKC Isoforms :

In Vitro

Danazol (0-100 μM, 18-72 h) inhibits the proliferation and the formation of capillary-like tubular structures in HUVECs^[2].
Danazol (5-20 μM, 48 h) inhibits melanogenesis in B16 cell with an IC₅₀ of 9.3 μM by post-transcriptionally inhibiting the expression of tyrosinase protein^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

HUVEC
Concentration:

0-100 μM
Incubation Time:

24-72 h
Result:

Inhibited the proliferation of HUVECs.

Western Blot Analysis^[2]

Cell Line:

B16
Concentration:

5-20 μM
Incubation Time:

48 h
Result:

Inhibited the expression of tyrosinase protein.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 17230-88-5
Appearance Solid
분자량 337.46
화학식 C₂₂H₂₇NO₂
Color White to off-white
SMILES

C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (4)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
Cardiovasc Drugs Ther

Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant. [Abstract]

2022 Feb;36(1):121-129. PMID: 33411110
Heliyon

Zhibai dihuang pill (ZBDH) exhibits therapeutic effects on idiopathic central sexual precocity in rats by modulating the gut microflora. [Abstract]

2024 Apr 16;10(9):e29723. PMID: 38707434

Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]

The rats were injected with Danazol on PND5 to induce the ICPP rat model of ICPP. The ICPP rats in the positive control group were further treated with ZBDH and GnRHa, respectively.

Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]

As shown by the results, the vaginal opening of Danazol-induced ICPP rats occurred on the PND17, which was significantly earlier than that of normal control rats; however, ZBDH and GnRHa treatments could effectively delay the vaginal opening time of ICPP rats.

Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]

The Danazol-induced idiopathic central precocious puberty (ICPP) rat model was successfully constructed and ZBDH increased the vaginal opening time. The normal estrus cycle was displayed.

Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]

The results revealed that ZBDH and GnRHa could inhibit the increase of serum hormones in Danazol-induced ICPP rats.
Res Sq

Sex differences in viral entry protein expression, host responses to SARS-CoV-2, and in vitro responses to sex steroid hormone treatment in COVID-19. [Abstract]

2020 Dec 31:rs.3.rs-100914. PMID: 33173861

용액&용해도

In Vitro:

DMSO : 25 mg/mL (74.08 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 20 mg/mL (59.27 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9633 mL

14.8166 mL

29.6331 mL

5 mM

0.5927 mL

2.9633 mL

5.9266 mL

10 mM

0.2963 mL

1.4817 mL

2.9633 mL

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.41 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Thomas GW, et al., Effects of danazol on endothelial cell function and angiogenesis. Fertil Steril. 2007 Oct;88(4 Suppl):1065-70. [Content Brief]

[2]. Chang TS, Lin JJ. Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch Pharm Res. 2010 Dec;33(12):1959-65. [Content Brief]

[3]. Deka SJ, et al., Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells. Chem Biol Drug Des. 2017 Jun;89(6):953-963. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.9633 mL	14.8166 mL	29.6331 mL	74.0829 mL
	5 mM	0.5927 mL	2.9633 mL	5.9266 mL	14.8166 mL
	10 mM	0.2963 mL	1.4817 mL	2.9633 mL	7.4083 mL
	15 mM	0.1976 mL	0.9878 mL	1.9755 mL	4.9389 mL
	20 mM	0.1482 mL	0.7408 mL	1.4817 mL	3.7041 mL
	25 mM	0.1185 mL	0.5927 mL	1.1853 mL	2.9633 mL
	30 mM	0.0988 mL	0.4939 mL	0.9878 mL	2.4694 mL
	40 mM	0.0741 mL	0.3704 mL	0.7408 mL	1.8521 mL
	50 mM	0.0593 mL	0.2963 mL	0.5927 mL	1.4817 mL
DMSO	60 mM	0.0494 mL	0.2469 mL	0.4939 mL	1.2347 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Danazol

Apoptosis Compound Library

Epigenetics Compound Library

Metabolism/Protease Compound Library

TGF-beta/Smad Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Anti-Aging Natural Product Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) Danazol

All PKC Isoforms

Biological Activity

Chemical Information

Publications (4)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Danazol Related Classifications

HY-B1029 Related Classifications